AGS-003 immunotherapy for kidney cancer

Participants will be randomized to one of two study groups: Group II will receive regular medications only for kidney cancer and a Group I will receive regular medications for kidney cancer plus AGS-003, created from a piece of the participant’s tumor along with his or her white blood cells, to activate the immune system. If randomized to Group I, leukapheresis will be done per local procedures and guidelines at a Red Cross Center in Ashley, PA. In most cases, a single leukapheresis session (about 4 hours) will provide enough white blood cells to make the participant’s AGS-003 for the entire study; however, a repeat session may be scheduled (with the participant’s consent). The study will comprise 8 clinic visits and last about 48 weeks, with a final visit scheduled within 30 days after study treatment ends. Participants will be followed by phone every 3 months for at least 3 years.